Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 14
Submit an article Journal homepage
216
Views
18
CrossRef citations to date
0
Altmetric
Review

Selective progesterone receptor modulators 1: use during pregnancy

Giuseppe Benagiano Professor and Dean University ‘la Sapienza’, Postgraduate School of Gynaecology and Obstetrics, Policlinico Umberto I°, Viale Regina Margherita 245, 00161 Roma, Italy
, MD PhD FACOG(hon) FRCOG(ad eundem) Hon Sen(Szeged),
Carlo Bastianelli Associate Professor University ‘la Sapienza’, Department of Gynaecology and Obstetrics, Policlinico Umberto I°, Viale Regina Margherita 245, 00161 Roma, Italy
, MD PhD &
Manuela Farris Research Associate University ‘la Sapienza’, Department of Gynaecology and Obstetrics, Policlinico Umberto I°, Viale Regina Margherita 245, 00161 Roma, Italy +39 06 490 398; +39 06 4997 2455; [email protected]
, MD PhD
Pages 2459-2472 | Published online: 08 Sep 2008

Bibliography

  • Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 1999;54:291-313
  • Dijkema R, Schoonen WGEJ, Teuwen R, et al. Human progesterone receptor A and B isoforms in CHO cells. 1. Stable transfection of receptor and receptor-responsive reporter genes: transcription modulation by (anti) progestagens. J Steroid Bio Chem Mol Biol 1998;64:147-56
  • Gronemeijer H, Meyer M-E, Bocquel M-TH, et al. Progestin receptors: isoforms and antihormone action. J Steroid Biochem 1991;40:271-8
  • Spitz IM, Bardin CW. Clinical pharmacology of RU 486 – an antiprogestin and antiglucocorticoid. Contraception 1993;48:403-518
  • Ilenchuck TT, Walters MR. Rat uterine progesterone receptor analyzed by tritiated R-5020 photoaffinity labelling; evidence that the A and B subunits are not equimolar. Endocrinology 1987;120:1449-56
  • Christensen K, Estes P, Onate S, et al. Characterization and functional properties of the A and B forms of human progesterone receptors synthesized in a baculovirus system. Mol Endocrinol 1990;24:1465-73
  • Conneely OM, Mulac-Jerevic B, Lydon JP. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 2003;68:771-8
  • Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307
  • Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 2000;65:807-15
  • Benagiano G, Farris M, Primiero FM. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Healthcare 2004;9:182-93
  • Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003;68:981-93
  • Klein-Hitpass L, Cato AC, Henderson D, Ryffel GU. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res 1991;19:1227-34
  • Liu Z, Auboeuf D, Wong J, et al. Coactivator/Corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA 2002;99:7940-4
  • Elger W, Bartley J, Schneider B, et al. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-23
  • Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulation: development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38
  • Baulieu EE. RU 486 – a decade on, today and tomorrow. In: Donaldson MS, Dorflinger L, Brown SS, et al, editors, Clinical applications of mifespristone RU 486 and other antiprogestins. Washington: National Academy Press; 1993. p. 71-119
  • Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 1996;36:47-81
  • Mahajan DK, London SN. Mifepristone (RU486): a review. Fertil Steril 1997;68:967-76
  • Bygdeman M, Swahn ML. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985;32:45-51
  • Baird DT. Mode of action of medical methods of abortion. J Am Med Womens Assoc 2000;55(3 Suppl):121-6
  • Cameron ST, Glasier AF, Narvekar N, et al. Effects of onapristone on postmenopausal endometrium. Steroids 2003;68:1053-9
  • Cameron ST, Critchley HO, Thong KJ, et al. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996;11:2518-26
  • Blithe DL, Niemanm LK, Blye RP, et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 2003;68:1013-7
  • Attardi BJ, Burgenson J, Hild SA, et al. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002;188:111-23
  • Kloostenboer HJ, Deckers GH, De Gooyer ME, et al. Pharmacological properties of a new selective antigestagen: ORG 3368. Ann NY Acad Sci 1995;761:192-201
  • Verbost PM, Kloosterboer HI, Schoonen WGJE, et al. Differential antiprogestin potencies: ORG 31710 vs ORG 33628 for menstrual induction in desogestrel-treated monkeys. In: The Endocrine Society: Program and Abstracts of the 80th Annual Meeting; Bethesda: The Endocrine Society; 1998. p. 256
  • Negro-Vilar A. New progestins and potential actions. J Soc Gynecol Invest 2000;7:S53-4
  • Philibert D, Deraedt R, Teutsch G. RU 38486: a potent antiglucocorticoid in vivo. In: Proceedings of the Seventh International Congress of Pharmacology. Tokyo, Japan; 1981
  • Ulmann A, Teutsch G, Philibert D. RU 486. Sci Am 1990;262:42-8
  • Herrmann W, Wyss R, Riondel A, et al. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. CR Acad Sci Paris 1982;294:933-8
  • Donaldson MS, Dorflinger L, Brown SS, Benet LS, editors. Clinical applications of mifespristone RU 486 and other antiprogestins. Washington: National Academy Press; 1993
  • Van Look PFA, Von Hertzen H. Antiprogestins: perspective from a global research. In: Donaldson MS, Dorflinger L, Brown SS, Benet LS, editors, Clinical applications of mifespristone RU 486 and other antiprogestins. Washington: National Academy Press; 1993. p. 253-77
  • Beier HM, Spitz IM. Progesterone antagonists in reproductive medicine and oncology. Hum Reprod 1994;9(Suppl 1)
  • Benagiano G, Primiero FM. The potential use of antiprogestins in gynaecological disorders. In: Motta M, Serio M, editors, Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects. Amsterdam: Elsevier Science; 1994. p. 391-9
  • Agarwal MK. Antihormonal steroids revisited. Drugs Future 1995;20:903-10
  • Tang OS, Ho PC. Clinical applications of mifepristone. Gynecol Endocrinol 2006;22:655-9
  • Chwalisz K. The use of progesterone antagonists for cervical ripening and as an adjunct to labour and delivery. Hum Reprod 1994;9(Suppl 1):131-61
  • Royal College of Obstetricians and Gynaecologists Study Group. Recommendations from the 33rd RCOG Study Group. In: Grudzinkas JG, O'Brien PMS, editors, Problems in early pregnancy: advances in diagnosis and management. London: RCOG Press; 1997. p. 327-31
  • Wagaarachchi PT, Ashok PW, Narvekar N, et al. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod 2001;16:1849-53
  • Hemminki E. Treatment of miscarriage: current practice and rationale. Obstet Gynecol 1998;179:397-8
  • Chen BA, Creinin MD. Contemporary management of early pregnancy failure. Clin Obstet Gynecol 2007;50:67-88
  • Nielsen S, Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet 1995;345:84-6
  • Jurkovic D, Ross JA, Nicolaides KH. Expectant management of missed miscarriage. Br J Obstet Gynaecol 1998;105:670-1
  • Bagratee JS, Khullar V, Regan L, et al. Randomised-controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod 2004;19:266-71
  • El-Rafeay H, Hinshaw K, Henshaw R, et al. Medical management of missed abortion and anembryonic pregnancy. BMJ 1992;305:1399-403
  • Lelaidier C, Baton-Saint-Mleux C, Fernandez H, et al. Mifepristone (RU486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod 1993;8:492-5
  • Schaff EA, Fielding SL, Eisinger S, Stadalius L. Mifepristone and misoprostol for early abortion when no gestational sac is present. Contraception 2001;63:251-4
  • Wagaarachchi PT, Ashok PW, Smith NC, Templeton A. Medical management of early fetal demise using sublingual misoprostol. Br J Obstet Gynaecol 2002;109:462-5
  • Gronlund A, Gronlund L, Clevin L, et al. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand 2002;81:1060-5
  • Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JP. Expectant, medical, or surgical management of first-trimester miscarriage: a meta-analysis. Obstet Gynecol 2005;105:1104-13
  • Hughes J, Ryan M, Hinshaw K, et al. The costs of treating miscarriage: a comparison of medical and surgical management. Br J Obstet Gynaecol 1996;103:1217-21
  • Fletcher HM, Wharfe G, Simeon D, et al. Induction of labour with intravaginal misoprostol versus dinoprostone in intrauterine death: a retrospective study. J Obstet Gynaecol 1996;16:155-8
  • Bugalho A, Bique C, Machungo F, Faundes A. Induction of labour with intravaginal misoprostol in intrauterine fetal death. Am J Obstet Gynecol 1994;171:538-41
  • Cabrol D, Bouvier D'yvoire M, Mermet E, et al. Induction of labour with mifepristone after intrauterine fetal death. Lancet 1985;2:1019
  • Cabrol D, Dubois C, Cronje H, et al. Induction of labor with mifepristone (RU486) in intrauterine fetal death. Am J Obstet Gynecol 1990;163:540-2
  • Vayrynen W, Heikinheimo O, Nuutila M. Misoprostol-only versus mifepristone plus misoprostol in induction of labour following intrauterine fetal death. Acta Obstet Gynecol Scand 2007;86:701-5
  • Wagaarachchi PT, Ashok PW, Narvekar N, et al. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. Br J Obstet Gynaecol 2002;109:443-7
  • Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev 2006;3:CD002253
  • Neilson JP. Mifepristone for induction of labour. Cochrane Database System Rev 2000;4:CD002865
  • Elliott CL, Brennand JE, Calder AA. The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstet Gynecol 1998;92:804-9
  • Hill NC, Selinger M, Ferguson J, Mackenzie IZ. The placental transfer of mifepristone (RU486) during the second trimester and its influence upon maternal and fetal steroid concentrations. Br J Obstet Gynaecol 1990;97:406-11
  • Wing DA, Fassett MJ, Mishell DR. Mifepristone for preinduction of cervical ripening beyond 41 weeks' gestation: a randomized controlled trial. Obstet Gynecol 2000;96:543-8
  • Fassett MJ, Wing DA. Uterine activity after oral mifepristone administration in human pregnancies beyond 41 weeks' gestation. Gynecol Obstet Invest 2008;62:112-5
  • Paris FX, Henry-Suchet J, Tesquier L, et al. Effect of an antiprogesterone (RU 486) on extra-uterine pregnancy. Rev Fr Gynecol Obstet 1986;81:33-5
  • Das C, Catt KJ. Antifertility actions of the progesterone antagonist RU 486 include direct inhibition of placental hormone secretion. Lancet 1987;2(8559):599-601
  • Wolf JP, Hsiu JG, Anderson TL, et al. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 1989;52:1055-060
  • Sowter MC, Farquhar CM. Ectopic pregnancy: an update. Curr Opin Obstet Gynecol 2004;16:289-93
  • Aubeny E, Peyron R, Larquier-Turpin C, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil 1995;40(Suppl 2):85-91
  • Jain JK, Dutton C, Harwood B, et al. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 2002;17:1477-82
  • Von Hertzen H, Honkanen H, Piaggio G, et al. For the world health organisation research group on post-ovulatory methods for fertility regulation: WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I. Efficacy. Br J Obstet Gynaecol 2003;110:808-18
  • Honkanen H, Piaggio G, Von Hertzen H, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. II. Side effects and women's perceptions. Br J Obstet Gynaecol 2004;111:715-25
  • Guest J, Chien PF, Thomson MA, Kosseim ML. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. Br J Obstet Gynaecol 2007;114:207-15
  • Heikinheimo O, Leminen R, Suhonen S. Termination of early pregnancy using flexible, low-dose mifepristone–misoprostol regimens. Contraception 2007;76:456-60
  • Van Bogaert LJ, Sedibe TM. Efficacy of a single misoprostol regimen in the first and second trimester termination of pregnancy. J Obstet Gynaecol 2007;27:510-2
  • Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997;90:88-92
  • Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-7
  • Ashok PW, Flett GM, Templeton A. Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study. Am J Obstet Gynecol 2000;183:998-1002
  • Bartley J, Tong S, Everington D, Baird DT. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception 2000;62:297-303
  • World Health Organisation, Task Force On Postovulatory Methods Of Fertility Regulation: Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532-7
  • Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med 2000;342:946-56
  • Baird DT, Sukcharoen N, Thong KJ. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Hum Reprod 1995;10:1521-7
  • Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998;13:2962-5
  • Parashar P, Iversen OE, Midboe G, et al. Medical abortion in the first trimester: the use of serum hCG and endometrial thickness as markers of completeness. Eur J Contracept Reproduct Health Care 2007;16:1-6
  • Kulier R, Giilmezoglu AM, Hofmeyr GJ, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2004;3:CD001328
  • Sinave C, Le Templier G, Bluin D, et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002;35:1441-3
  • ACOG Practice Bulletin: medical management of abortion. Obstet Gynecol 2005;106:871-82
  • Creinin M, Blumenthal P, Shulman L. Mifepristone–Misoprostol medical abortion mortality. Med Gen Med 2006;8:26
  • Puri CP, Patil RK, Elger WA, Pongubala JM. Effects of progesterone antagonist ZK 98.299 on early pregnancy and foetal outcome in bonnet monkeys. Contraception 1990;41:197-205
  • Ashok PW, Kidd A, Flett GMM, et al. A randomized comparison of medical abortion and surgical vacuum aspiration at 10 – 13 weeks gestation. Hum Reprod 2002;17:92-8
  • Rodger MW, Baird DT. Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. Br J Obstet Gynaecol 1990;97:41-5
  • Gouk EV, Lincoln K, Khair A, et al. Medical termination of pregnancy at 63–83 days gestation. Br J Obstet Gynaecol 1999;106:535-9
  • Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases. Am J Obstet Gynecol 2003;188:1315-9
  • Bracken H, Ngoc NT, Schaff E, et al. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion. Obstet Gynecol 2007;109:895-901
  • Hamoda H, Ashok PW, Flett GMM, Templeton A. A randomised trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13–20 weeks gestation. Hum Reprod 2003;20:2348-54
  • Nilas L, Glavind-Kristensen M, Veihorg T, Knudsen WI. One or two day mifepristone–misoprostol interval for second trimester abortion. Acta Obstet Gynecol Scand 2007;86:1117-21
  • Kapp N, Borgatta L, Stubblefield P, et al. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol 2007;110:1304-10
  • Creinin MD, Schreiber CA, Bednarek P, et al. Medical Abortion at the Same Time (MAST) Study trial group. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol 2007;109:885-94
  • Ho PC, Blumenthal PD, Gemzell-Danielsson SK, et al. Misoprostol for the termination of pregnancy with a live foetus at 13 to 26 weeks. Int J Obstet Gynecol 2007;99:S178-81
  • Lohr P, Hayes J, Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. Cochrane Database Syst Rev 2008;1:CD006714
  • Clark WH, Gold M, Grossman D, Winikoff B. Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. Contraception 2007;75:245-50

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.